Table 1.
Systematic literature review search results
| Author | Year | Study design | Menopausal status | Total receiving NET (n) | Clinically node-positive patients (n) | Stage | Breast cancer subtype | NET regimen | Nodal response in cN+ | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dixon | 2011 | Prospective clinical trial | Postmenopausal women | 61 (40 had surgery) | 28 (Unclear who had surgery) | Stage II–IV | Invasive lobular carcinoma | ≥ 3 Months letrozole | 0% cN+ became node (−) at surgery |
| 2 | Fontein | 2014 | Randomized control trial | Postmenopausal women | 102 | 25 | Stage I–III | All Invasive Breast Cancer | 6 Months Exemestane | 3/25 (12%) pCR |
| 3 | Thorton | 2019 | NCDB retrospective review (2004–2014) | Pre- and postmenopausal | 855 | 855 | Stage I–III | Invasive lobular Carcinoma | All NET |
69 (8.1%) pCR; 8 (0.9%) Downstage, 355 (41.5%) No Change, 304 (35.6%) Upstage |
| 4 | Weiss | 2019 | NCDB retrospective review (2012–2015) | Pre and postmenopausal | 2138 | 571 | Stage II–III | All invasive breast cancer | All NET | Nodal pCR 76/571 (13.3%) |
NET neoadjuvant endocrine therapy, cN clinical node status, pCR pathologic complete response, HR+ hormone receptor-positive